

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Applied Research Systems ARS Holding N.V.	04/08/2004
RECEIVING PARTY DATA	
Name:	Solexa Ltd.
Street Address:	Little Chesterford
Internal Address:	Saffron Walden
City:	Essex
State/Country:	UNITED KINGDOM
Postal Code:	CB10 1XL
Name:	Lynx Therapeutics Inc.
Street Address:	25861 Industrial Boulevard
City:	Hayward
State/Country:	CALIFORNIA
Postal Code:	94545
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11506146
CORRESPONDENCE DATA	
Fax Number:	(858)736-8428
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(858) 246-8842
Email:	ip@illumina.com
Correspondent Name:	Tiffany B. Thomas
Address Line 1:	9885 Towne Centre Drive
Address Line 2:	Legal Department
Address Line 4:	San Diego, CALIFORNIA 92121

CH \$40.00 11506146

ATTORNEY DOCKET NUMBER:	IP-0345A-US
NAME OF SUBMITTER:	Irja Zarembok
Total Attachments: 2 source=Assignment to Solexa Ltd#page1.tif source=Assignment to Solexa Ltd#page2.tif	

FORM OF ASSIGNMENT OF PATENTS

PATENT ASSIGNMENT

PARTIES:

- (1) Applied Research Systems ARS Holding N.V., Pietermaai 15, Curaçao,
The Netherlands Antilles

("ASSIGNOR")

- (2) Solexa Ltd., Little Chesterford, Saffron Walden, Essex CB10 1XL, Great Britain, and
Lynx Therapeutics Inc., 25861 Industrial Boulevard, Hayward, CA 94545, United States

("ASSIGNEES")

RECITALS:

- A. The ASSIGNOR is registered as proprietor of the patent applications/patents (please see the enclosed listing) (the "APPLICATION(S)/PATENT(S)").
- B. The parties have agreed that all rights in the APPLICATION(S)/PATENT(S) should be assigned to the ASSIGNEES.

OPERATIVE TERMS:

1. Assignment

In consideration of the sum of US\$1 and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged by the ASSIGNOR) the ASSIGNOR hereby assigns to the ASSIGNEES and the ASSIGNEES hereby accepts all the ASSIGNOR's property right title and interest in and to the APPLICATION(S)/PATENT(S) including without limitation:

- (a) the full title of the APPLICATION(S)/PATENTS;
- (b) the right to file for and have granted in the ASSIGNEES' names divisionals, continuations, continuations in part, extensions and SPCs as appropriate;
- (c) the benefit of all priority dates;
- (d) the right to seek and obtain registrations in other countries;
- (e) the right to sue for and obtain injunctive relief, damages and all other relief in respect of any infringement or misuse (whether past present or future) of the APPLICATION(S)/PATENT(S) or any patents deriving from any of the same.

2. Authorisation

The ASSIGNOR hereby authorises the ASSIGNEES and the ASSIGNEES' agents to sign all such forms on behalf of the ASSIGNOR as the ASSIGNEES consider appropriate in order to record the APPLICATION(S)/PATENT(S) in the name of the ASSIGNEES.

3. Law

This Assignment shall be governed by and construed and take effect in accordance with Swiss law.

Any dispute, controversy or claim arising out of or in relation to this Assignment, including the validity, invalidity, breach or termination thereof, shall be settled by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers of Commerce in force on the date when the Notice of Arbitration is submitted in accordance with these Rules. The number of arbitrators shall be one. The seat of the arbitration shall be in Geneva. The arbitral proceedings shall be conducted in English language.

IN WITNESS of which the parties have executed this Assignment in accordance with their statutes by duly authorised officers effective on the date of the later signature.

EXECUTED by the ASSIGNOR:


EXECUTED by the ASSIGNEES:

For Solexa Ltd.


For Lynx

Therapeutics, Inc.

Signature: _____



Signature: _____



Signature: _____

Name: Giampiero DE LUCA

Name: MICHAEL McCLOTTEN Name:

Title: Authorised representative

Title: CEO Title:

Date: _____

April 8, 2004

Date: _____

13 May 2004

Date: _____